Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Incidence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer
12 evidence topics · 10 sources
U.S. estimated new cases and deaths, 2026
U.S. incidence rate of female breast cancer per 100,000
U.S. incidence rate of HR-positive/HER2-negative breast cancer per 100,000
U.S. share of cases that are HR-positive/HER2-negative, by race and ethnicity
U.S. incidence trends, all stages and distant stage
U.S. annual new metastatic diagnoses, de novo and recurrent
U.S. new metastatic female breast cancer cases, 2018 estimate and 2025 projection
| Measure | Breast (female) |
|---|---|
| Number of new metastatic cancer cases, de novo (observed), 2018 | “15 800”View highlighted excerpt for this quote |
| Number of new metastatic cancer cases, de novo and recurrence (estimated), 2018 | “46 666”View highlighted excerpt for this quote |
| Projected number of new metastatic (de novo and recurrence) cancer cases, 2025 | “52 126”View highlighted excerpt for this quote |
Risk of distant recurrence after 5 years of adjuvant endocrine therapy for ER-positive disease
“Breast-cancer recurrences occurred at a steady rate throughout the study period from 5 to 20 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the patients with stage T1 disease, the risk of distant recurrence was 13% with no nodal involvement (T1N0), 20% with one to three nodes involved (T1N1–3), and 34% with four to nine nodes involved (T1N4–9); among those with stage T2 disease, the risks were 19% with T2N0, 26% with T2N1–3, and 41% with T2N4–9.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide incidence, GLOBOCAN 2024
“With an estimated 2.4 million new cases and 694,000 deaths, female breast cancer is the second most commonly diagnosed cancer and the fourth leading cause of cancer death in 2024, accounting for 11.8% of all cases and 7.1% of all deaths” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence rates are elevated in Australia/New Zealand, Northern America, and Northern Europe (90–102 per 100,000) and are approximately three times higher than those in Eastern Africa, South Central Asia, and Middle Africa (29–33 per 100,000;” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote